v3.26.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Segment Net Revenues and Loss The Company's reportable segment net revenues, significant segment expenses and consolidated profit (loss) for the quarters ended March 31, 2026 and 2025, consisted of the following (in thousands):

 

 

Three Months Ended March 31,

 

 

2026

 

 

2025

 

Revenues:

 

 

 

 

 

Grant Revenue

$

 

 

$

763

 

Collaboration revenue - related party

 

258

 

 

 

5,099

 

Collaboration revenue

 

 

 

 

12

 

Total revenues

 

258

 

 

 

5,874

 

 

 

 

 

 

 

Less:

 

 

 

 

 

Tebipenem HBr

 

412

 

 

 

8,669

 

SPR720

 

 

 

 

449

 

SPR206

 

 

 

 

49

 

Research and development personnel related (including share-based compensation)

 

1,669

 

 

 

3,337

 

Facility related and other, research and development

 

828

 

 

 

1,102

 

General and administrative personnel related (including share-based compensation)

 

2,290

 

 

 

4,118

 

Professional and consultant fees

 

1,681

 

 

 

2,263

 

Facility related and other, general and administrative

 

916

 

 

 

443

 

Other segment items*

 

1

 

 

 

174

 

Interest income

 

(336

)

 

 

(864

)

Consolidated loss

$

(7,203

)

 

$

(13,866

)

 

*Other segment items include restructuring charges, impairment of long-term asset and other income, net.